8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported) July 31, 2014

E. I. du Pont de Nemours and Company

(Exact Name of Registrant as Specified in Its Charter)

Delaware	1-815	51-0014090
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
Of Incorporation)	File Number)	Identification No.)

1007 Market Street

Wilmington, Delaware 19898

(Address of principal executive offices)

Registrant’s telephone number, including area code:   (302) 774-1000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) Election of Director

On July 31, 2014, the Board of Directors, upon recommendation of the Corporate Governance Committee, elected Ulf M. "Mark" Schneider as a new director, effective October 22, 2014. A copy of the press release announcing Mr. Schneider's election is attached hereto as Exhibit 99.1.

At the present time, Mr. Schneider has not been named to any committee of the Board of Directors and it is premature to state which committee(s), if any, Mr. Schneider may expect to be named to in the future.

There is no arrangement or understanding between Mr. Schneider and any other person pursuant to which Mr. Schneider was elected as a director of the company. There are no transactions in which Mr. Schneider has an interest requiring disclosure under Item 404(a) of Regulation S-K.

Mr. Schneider will participate in the standard director compensation arrangements described on pages 15 through 18 of our 2014 Annual Meeting Proxy Statement, filed with the Commission on March 14, 2014.

Item 9.01Financial Statements and Exhibits.

(d)    Exhibits

The following exhibit is being furnished, not filed, pursuant to Item 5.02 of Form 8-K:

99.1    Press release, dated August 1, 2014, entitled "Mark Schneider Elected to DuPont Board of Directors."

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

E. I. DU PONT DE NEMOURS AND COMPANY

(Registrant)

/s/ Barry J. Niziolek

Barry J. Niziolek

Vice President and Controller

August 4, 2014

3

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press release, dated August 1, 2014, entitled "Mark Schneider Elected to DuPont Board of Directors."

4

EX-99.1

Exhibit 99.1

Contact:	Dan Turner
	302-774-0081
	daniel.a.turner@usa.dupont.com

Mark Schneider Elected to DuPont Board of Directors

WILMINGTON, Del., Aug. 1, 2014 - DuPont today announced the election of Ulf M. “Mark” Schneider, President and CEO of Fresenius SE & Co. KGaA to its board of directors, effective Oct. 22.

“Mark leads a significant global healthcare business and brings strong operating and international experience, including valuable perspective in emerging markets,” said DuPont Chair and Chief Executive Officer Ellen Kullman. “He will be a strong asset to DuPont as we continue to advance our strategy and bring the strength of our science to bear on some of the world’s most pressing challenges.”

Mr. Schneider, 48, has served since 2003 as President and CEO for Fresenius SE & Co. KGaA, a diversified global health care group, with $27.0 billion in revenue in 2013. Fresenius operates in approximately 100 countries and specializes in lifesaving medicines and technologies for dialysis, clinical nutrition, infusion and transfusion. Mr. Schneider joined Fresenius in 2001, serving as CFO of Fresenius Medical Care, a Fresenius Group company. Previously, he was Group Finance Director of Gehe UK, a UK-based pharmaceutical distributor and held several senior executive positions with Franz Haniel & Cie, GmbH, a diversified German multinational company, since 1989.

Mr. Schneider graduated from the University of St. Gallen in Switzerland, where he also received a doctoral degree in Economics, and earned his MBA from Harvard Business School.

DuPont (NYSE: DD) has been bringing world-class science and engineering to the global marketplace in the form of innovative products, materials, and services since 1802.  The company believes that by collaborating with customers, governments, NGOs, and thought leaders we can help find solutions to such global challenges as providing enough healthy food for people everywhere, decreasing dependence on fossil fuels, and protecting life and the environment.  For additional information about DuPont and its commitment to inclusive innovation, please visit http://www.dupont.com.

# # #

8/1/14

E. I. du Pont de Nemours and Company